PREVALENCE AND PROGNOSTIC VALUE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS HOSPITALIZED WITH DECOMPENSATED CHRONIC HEART FAILURE

Aim To study the incidence and effect of non-alcoholic fatty liver disease (NAFLD) on clinical outcomes in patients with decompensated chronic heart failure (DCHF). Material and methods The study included 338 patients with NYHA functional class III-IV DCHF (51.2% men, mean age 72.8 +/- 11.7 years), arterial hypertension (AH) in 90%, myocardial infarction in 37 %, atrial fibrillation in 64 %, chronic kidney disease (CKD) in 42%, type 2 diabetes mellitus (T2DM) in 35 %, left ventricular ejection fraction (LVEF) <40% in 27 %. NAFLD was diagnosed based on the 2021 Clinical Guidelines of the Russian Scientific Medical Society of Therapists and the Scientific Society of Gastroenterologists of Russia. The stage of liver steatosis was determined using transient elastometry with assessment of the controlled attenuation parameter (CAP) of ultrasound (S, dB/m) using a FibroScan device. Threshold CAP values <294 dB/m corresponded to the degree of steatosis: S0; S1, 295-309 dB/m; S2, 310-330 dB/m; S3, >= 331 dB/m. Results NAFLD was diagnosed in 28.9% of patients. The patients were divided into two groups: group 1 included patients with CHF and NAFLD (n=98 (28.9%), 50.0 % men) and group 2 included patients with CHF without NAFLD (n=240 (71.0 %), 51.6% men). A multivariate regression analysis showed that independent predictors of NAFLD were systolic blood pressure >= 130 mm Hg (odds ratio (OR), 3.700; p <0.001), history of T2DM (OR, 2.807; p <0.005), and waist circumference >111 cm (OR, 2.530; p <0.012). Patients with CAP =331 dB /m (S3) had a worse prognosis during the 2-year follow-up for the composite adverse outcome (all-cause mortality + readmission) (Kaplan-Meier curves Log-Rank p=0.035). Conclusions NAFLD was detected in almost one-third of patients hospitalized for DCHF. AH, T2DM, and abdominal obesity were associated with a high risk of NAFLD. However, only severe steatosis (S3) was an independent predictor of adverse clinical outcomes during a 2-year period after adjustment for known risk factors.